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Bariatric surgery has proven to be a life-saving measure for some, but for others it has precipitated a plethora of metabolic
complications ranging from mild to life-threatening, sometimes to the point of requiring surgical revision. Obesity was previously
thought to be bone protective, but this is indeed not the case. Morbidly obese individuals are at risk for metabolic bone
disease (MBD) due to chronic vitamin D deﬁciency, inadequate calcium intake, sedentary lifestyle, chronic dieting, underlying
chronic diseases, and the use of certain medications used to treat those diseases. After bariatric surgery, the risk for bone-related
problems is even greater, owing to severely restricted intake, malabsorption, poor compliance with prescribed supplements, and
dramatic weight loss. Patients presenting for bariatric surgery should be evaluated for MBD and receive appropriate presurgical
interventions. Furthermore, every patient who has undergone bariatric surgery should receive meticulous lifetime monitoring, as
the risk for developing MBD remains ever present.
1.Introduction
Although obesity is noted throughout recorded history, the
prevalence of obesity rapidly reached pandemic proportions
during the second half of the 20th century. Paralleling the
pandemic, surgical treatment approaches came into vogue,
stemming at least in part from the observation that patients
who had undergone gastrectomy experienced signiﬁcant and
durable weight loss. It was not until the early 1970s when the
development of metabolic bone disease was linked to gas-
trointestinal surgeries, most notably following gastrectomy,
that rapidly became a well-known cause of osteomalacia.
Advances in the ﬁeld of bariatric surgery have addressed
many of the more serious postoperative complications in
spite of the untoward consequences of bariatric surgery and
dramatic weight loss on skeletal health persist.
2.NormalNutrientAbsorption:
It Is All about the Bones
Recalling the nutrients essential for bone health and their
primary sites of gut absorption helps to illustrate why
metabolicbonediseaseiscommonlyseeninbariatricsurgery
patients (Figure 1).
Minerals such as calcium, magnesium, and many trace
elements are absorbed predominantly in the proximal small
bowel. Calcium absorption is also driven by physiologic
need and can be absorbed via active transport throughout
the duodenum, the ileum, and, to a lesser degree, the
jejunum and colon when need be [1]. Proteins and fats
are absorbed in the proximal bowel after the prerequisite
actions of pancreatic enzymes. The water-soluble vitamins
are absorbed in the proximal small bowel with the exception
of B12 which is absorbed principally in the terminal ileum.
Vitamin D and the other so-called “fat-soluble” vitamins are
mainly absorbed by passive diﬀusion in the proximal and
mid small intestine in a process that is not fat-dependant
per se but highly dependant on the presence of bile salts
[2–4].
3.BariatricSurgeryandMBD:
A CausalRelationship Established
Gastrointestinal surgeries resulting in weight loss had
their beginnings in the 1940s originally designed to treat,
among other maladies, gastric ulcers. By the early 1950’s
this clinical observation led to the ﬁrst intestinal bypass
surgeries performed expressly for weight reduction. The2 Journal of Obesity
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earliest procedures bypassed a great deal more of the small
intestine than modern day procedures and did indeed result
in dramatic weight loss but were accompanied by severe
diarrhea, electrolyte imbalance, hepatic failure, and a high
rate of mortality. In the 1960s procedures such as the “14–
4” jejuno-ileal bypass where all by 14inches of proximal
jejunum were bypassed and anastamosed to the terminal
ileum (4inches), promoted signiﬁcant weight loss with rela-
tively fewer complications but severe malabsorption, protein
and vitamin deﬁciencies, renal oxalate stones, and hepatic
failure led to unacceptable complication and mortality rates
[5].
The ﬁrst articles identifying metabolic bone disease fol-
lowinggastrointestinalsurgerieswerepublishedinthe1970’s
most notably following gastrectomy and jejuno-ileal bypass
[6]. In fact, the prevalence and severity of nephrolithiasis
following the 14–4 surgery necessitated surgical reversal in
many patients by the ﬁfth postsurgical year, and forced the
abandonment of the procedure later that decade.
Since then, publications citing a causal relationship
between bariatric surgery and metabolic bone disease num-
ber into the multiple of hundreds. The time from surgery
to diagnosis ranges from 8 weeks to greater than 32 years,
and no bariatric procedure to date has been exempt [7–12].
But undoubtedly the most profound clinical ﬁndings have
been in older patients who underwent weight loss surgery
in the 1970s and were subsequently treated for chronic
renal oxalate stones and “severe osteoporosis” when in fact
chronic, severe malabsorption, and steatorrhea resulted in
profound metabolic derangement, nutrient deﬁciencies, and
osteomalacia [9, 13].
Today there are multiple, safe, eﬀective bariatric proce-
dures that are classiﬁed by their predominant mechanism of
action.Restrictiveproceduressuchasgastricbandingandthe
gastric sleeve promote weight loss by reducing the size of the
stomach thereby severely limiting oral intake. Malabsorptive
procedures bypass some portion of the small intestine and
promote weight loss by decreasing the absorption of calorie-
containing nutrients. And combination procedures, such as
the Roux-en-Y gastric bypass and biliopancreatic diversion,
limitthesizeofthestomachaswellasbypasspartofthesmall
intestine.
Exclusively restrictive procedures, formerly presumed
not to alter bone metabolism, appear to place patients at
risk of MBD due to inadequate intake of calcium, vitamin
D, and protein [14, 15]. Regardless of the surgical procedure,
profound deﬁciencies can and do occur and as a result,
all patients who have undergone a surgical weight loss
procedure should undergo routine screenings for metabolic
bone disease.
4.VoluntaryWeightLoss:
Involuntary Bone Loss
Voluntary weight loss of approximately 10% on the part of
an obese or overweight individual, whether it is achieved as
a result of bariatric surgery or dieting, results in bone loss
at all sites of 1-2% [16–19]. This loss appears to vary among
populations in that premenopausal women less than 45 years
of age may be able to lose a moderate amount of weight
without a signiﬁcant increase in fracture risk, while a study
of overweight men found a 7% weight loss resulted in a 1%
bone loss [20].
Speciﬁcally, weight reduction decreases calcium absorp-
tion through several proposed mechanisms, with a subse-
quent rise in PTH and increase in bone resorption, and the
percentage of bone lost as a result of weight loss correlates
strongly with the velocity at which the weight is lost.
Proposed mechanisms include eﬀects due to increased levels
of circulating cortisol, and decreased levels of circulating
estrogen, IGF-1, leptin, ghrelin, and GLP-2, particularly in
patients who have undergone bariatric surgery [20].
Postsurgically, rapid weight loss of 50kg to greater than
100kgisnotuncommonamongsuccessfulbariatricpatients,
and this combined with severely restricted oral intake,
decreased calcium absorption, and vitamin D deﬁciency
places these patients at extremely high risk for the rapid
development of MBD [10, 21, 22]. One large study noted
the development of metabolic bone disease in greater
than 70% of patients having undergone a malabsorptive
procedure, a second study detected increased markers of
bone resorption as soon as 8 weeks after bariatric surgery,
regardless of whether the patient underwent a malabsorptive
or restrictive bariatric procedure, and yet another study
that examined patients 12 months after undergoing gastric
banding found that 48% had a statistically signiﬁcant bone
mineral reduction of greater than three percent [7, 9,14].
Attempts to protect the skeleton and mitigate the activa-
tion of the calcium-PTH axis during weight reduction with
supplementalcalciumandvitaminDhavehadmixed results.
One current hypothesis supports the fact that the usual
recommended intake of calcium is inadequate to during
weight loss, and higher levels of 1600–1800mg/day should
be recommended, while the required level of supplemental
Vitamin D during periods of rapid weight loss remains
unclear [23, 24].
Inadequate protein intake also has a detrimental eﬀect
on bone and may play a key role in the development of
MBD in this population. The intake of lean protein is highly
emphasized in the immediate postoperative period as a bodyJournal of Obesity 3
protein-sparing strategy; however tolerance, compliance,
and malabsorption issues frequently result in inadequate
intake and frank protein deﬁciency. This is discussed in
further detail below.
5.FourParadoxes ofBariatricsandMBD
As medical professionals, we made assumptions every day
regarding our patients, fostered at least in part by the ever-
increasing speed at which we must see, assess, diagnose, and
treat. Although many suppositions are both legitimate and
accurate, consider the following commonly made assump-
tions that are, in fact, fundamental paradoxes when it comes
to bariatric patients and the risk for metabolic bone disease.
5.1.Obesity / = Well-Nourished. Theﬁrstparadoxtoconsider
in approaching the morbidly obese patient is that the
presence of obesity does not equate to being well nourished.
In fact, body mass index (BMI) quantiﬁes body mass, not
nutrition status, and should not be presumed to be a
surrogate marker for the nutritional status of the individual.
Recognizing this fact allows the clinician to maintain an
appropriately high index of suspicion for underlying deﬁ-
ciencies that could serve as clues to the presence of metabolic
bone disease.
5.2. Morbid Obesity / = Better Bone Quality. Morbid obesity
has historically been viewed as having a protective eﬀect
against the development of osteoporosis. But the second
paradox to be attentive to in this population is that although
the bone mineral density as measured by dual-energy X-ray
absorptiometry (DXA) may be normal, it does not equate
to normal (or better) bone quality. In fact, sequestration of
vitamin D in the adipocytes, frank vitamin D and calcium
deﬁciencies, and secondary hyperparathyroidism (HPTH)
are common in extremely obese individuals presenting for
bariatric surgery, and all can have a profound eﬀect on
bone quality [8, 9, 21, 25]. Studies attempting to deﬁne the
prevalence of vitamin D deﬁciency have identiﬁed rates in
excessof60%amongpatientsselectedtoundergoweightloss
surgery [9, 26]. Similarly, the prevalence of elevated PTH in
this population ranges from 25% to 48% [9, 27].
5.3. Morbid Obesity / = Central DXA. The third paradox is
that bariatric surgery patients are at high risk for bone loss
but DXA, the gold standard for bone density measurement,
has limited utility in this population. Weight limitations of
DXA tables have typically been 250–275pounds. Newer and
larger machines can accommodate upwards of 450pounds
but this is still insuﬃcient to accommodate many bariatric
patients.ForearmDXAimagingremainstheonlystatistically
validated option for assessing bone mineral density and
fracture risk in patients who exceed the recommended table
weight limit, and should be used for presurgical screening
and postsurgical surveillance in this population.
The use of serial DXA in patients who have experienced
dramatic weight loss is not without controversy. Discussed
elsewhere in the literature, it is important to note that there
are some studies that have identiﬁed statistically signiﬁcant
accuracy errors in serial central DXA measurements in this
population [28].
5.4. Abnormal DXA / = Osteoporosis. Despite the presence
of long-standing morbid obesity, many patients will have
abnormally low bone mineral density test results. But
abnormal DXA results do not always represent primary
osteoporosis, and abnormal DXA results should never evoke
a “knee-jerk” reﬂex response on the part of the clinician
to diagnose osteoporosis and start a bisphosphonate. In
fact, indiscriminate use of bisphosphonates in this patient
population can result in life-threatening complications—
more on this in a moment.
Abnormal DXA in a bariatric surgery patient often
represents secondary bone disease due to nutritional deﬁ-
ciencies, and when secondary bone disease is present, it
should become the focus of treatment interventions. A clue
to the presence of secondary bone disease may be seen in
abnormally low Z-scores. Recall that Z-scores for a reference
population are matched to age as well as gender. If the bone
m i n e r a ld e n s i t yh a sc h a n g e do n l yb e c a u s eo fn o r m a la g i n g ,
Z-scores would be expected to be zero, however if the Z-
scores are signiﬁcantly low, this should raise the index of
suspicion as to the presence of underlying deﬁciencies.
6.CaseinPoint
T h eD X Ai m a g es e e ni nFigure 2 is the nondominant
forearm of a woman who recently presented for evaluation
and treatment of hypocalcemia. Her medical history was
remarkableforbariatricsurgeryin1974,chronicrenalstones
since 1979, and she had been wheelchair bound for 10
years due to numerous fragility fractures and profound
proximal weakness. Biochemical indices were signiﬁcant for
hypocalcemia, undetectable 25-hydroxyvitamin D, elevated
alkaline phosphatase, intact parathyroid hormone ﬁve times
the upper range of normal and very low urine calcium.
The T-scores clearly exceed the World Health Organization
criteria for osteoporosis, but the Z-scores in concert with the
clinical presentation are even more telling.
Delineating secondary bone disease from low peak bone
mass often requires additional clinical data and a skilled
specialist, but in this case the grossly abnormal biochemical
indices and patient presentation is suﬃcient to conﬁdently
make the correct diagnosis and select the appropriate course
of treatment.
7. Other Cluesto the Presenceof
Metabolic Bone Disease
Months to years prior to the diagnosis of metabolic bone
disease, many patients have nonspeciﬁc and vague symp-
toms that are often incorrectly diagnosed as ﬁbromyalgia,
rheumatoid arthritis, polymyalgia rheumatica, Paget disease,
ordepression[8].Butasinotheraspectsofclinicalmedicine,
there is still no substitute for a thorough history and physical
exam. Additionally, bariatric surgery patients should be4 Journal of Obesity
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Figure 2: DXA-Forearm.
askedabouttheirnutritionpracticesincludingproteinintake
and the use of supplements.
Proximal weakness or complaints of muscle loss; deep,
dull, poorly localizing bone pain, and increasing diﬃculty
arising from a chair or ascending a ﬂight of stairs all serve
as clues to the possible presence of vitamin D deﬁciency
andosteomalacia.Ahistoryoffrequentstooling,steatorrhea,
or kidney stones should also heighten clinical suspicion of
abnormal calcium metabolism and risk for bone loss.
Finally, undersupplementation in this patient population
can rapidly lead to MBD in that maintenance of normal
nutrition status and the associated lab parameters typically
requires daily protein and supplements in doses that far
exceed the current RDAs. It is imperative for clinicians to
have a high index of suspicion for the presence of MBD if a
patientreportstakingonlyanover-the-countermultivitamin
and 500mg of calcium daily, with little attention paid to the
diet.
8. CalciumOxalateStones
In the intact GI tract, bile acids and free fatty acids
are absorbed in the proximal intestine, calcium forms an
insoluble precipitate with oxalates, and calcium oxalates
are harmlessly excreted in the stool. In the malabsorptive
gut, unabsorbed fatty acids bind calcium thereby making
it unavailable to bind oxalates, and lingering bile acids and
free fatty acids promote increased colonic permeability. The
unbound oxalates are readily absorbed in the distal gut
resulting in hyperoxaluria thereby increasing the likelihood
of oxalate deposition in the renal parenchyma [29, 30]. One
recent study noted a mean time to the development of the
ﬁrst stone after roux-en-y gastric bypass (RNYGB) of 2.9
y e a r sw i t har a n g eo f1m o n t ht o1 3y e a r s[ 29].
Although there is evidence that a low-oxalate diet may
decrease the risk of stone formation by 20 percent, it is
important to keep in mind that dietary oxalates only account
for 10–20 percent of total oxalates, with hepatic synthesis
accounting for 40–50 percent, and ascorbic acid metabolism
accounting for the remaining 40–50 percent [31]. Oxalates
are a ubiquitous component of plants, cereal grains, leafy,
and root vegetables, therefore an oxalate-free diet is clearly
not possible, and further restriction of the diet following
bariatric surgery, with its inherent risks for nutritional
inadequacy, is inadvisable. Emphasis on adequate water
intake, avoidance of dietary fats and supplemental vitamin
C, and supplementation with calcium citrate which helps
to increase urinary pH and retard calcium oxalate crystal
formation, have all been demonstrated to be beneﬁcial in
preventingcalciumoxalatestonesinthispopulation[31–33].
9.2008 AACE/TOS/ASMBS Guidelines
T h e r eh a v eb e e naw i d ev a r i e t yo fr e c o m m e n d a t i o n sp u t
forth in the literature for perioperative screening, risk
stratiﬁcation, and management of MBD in bariatric patients
[34–37]. With the 2008 publication of the American Asso-
ciation of Clinical Endocrinologists, The Obesity Society,
and American Society for Metabolic and Bariatric Surgery
(AACE/TOS/ASMBS) medical guidelines for perioperative
support of the bariatric surgery patient, there are now
evidence-based practice guidelines that include recommen-
dations for testing and management of skeletal and mineral
disorders [38]. Although the guidelines serve as an excellentJournal of Obesity 5
general guide, essential information speciﬁcally addressing
bone disease in this population is still lacking. Speciﬁcally,
evidence-based guidelines need to be put forth regarding
presurgical bone assessment, the preferential use of calcium
citrate, the use of cholecalciferol (D3) over D2 or D analogs;
the eﬃcacy of UV-B light in patients resistant to oral reple-
tion; the risk for fat-soluble vitamin deﬁciencies with long-
term use of bile acid sequestrants commonly used to treat
postoperative diarrhea, and both the risks and questionable
eﬃcacy of oral bisphosphonates in this population.
10. Recommendations
Presurgically, in addition to the biochemical indices recom-
mended in the AACE/TOS/ASMBS guidelines which include
25-hydroxyvitamin D and a bone marker of resorption such
as urine n-telopeptide (NTX), obtain a baseline DXA, even
if only the forearm can be imaged because of weight limita-
tions. If the DXA is abnormal, pursue further investigation
and treatment as appropriate, with a high index of suspicion
for secondary bone disease.
Postsurgically, repeat the DXA in one year, then follow
the International Society for Clinical Densitometry (ISCD)
guidelines in determining when best to obtain future bone
density studies [39].
11. CalciumSupplementation
Calcium citrate has been demonstrated to have better
bioavailability, superior fractional uptake in bone, and
eﬃcacy in normalizing markers of bone turnover when com-
pared to other commercially available calcium supplements
[40]. Citrate is metabolized to bicarbonate which has a
neutralizing aﬀect on urine, thereby also decreasing the risk
of nephrolithiasis.
An optimal daily intake of calcium based on the speciﬁc
bariatric surgical procedure is currently unknown however
attempts to optimize calcium intake is essential, particularly
during periods of rapid weight loss [23, 24]. Absorption,
separate from the issue of compliance, can be problematic
for some patients, therefore judicious monitoring is advised.
It is important to remember that calcium homeostasis is a
tightly regulated process, maintained by a combination of
gut absorption, bone resorption, and renal reabsorption. In
the absence of adequate dietary calcium and/or absorption,
calcium will be resorbed from bone in order to support
calcium-dependant processes; therefore the serum calcium is
an unreliable measure of adequate calcium intake. Quanti-
fying urine calcium can assist in assessing the adequacy of
calcium intake in that abnormally low urine calcium in the
presenceofnormalrenalfunctionsuggestsinadequateintake
and/or absorption. Table 1 provides a summary of current
recommendations for this unique population [13, 41].
11.1. Vitamin D. Serum 25-hydroxyvitamin D remains the
most accurate marker of vitamin D status, and has well-
established, strong associations with vitamin D deﬁciency,
fragility fractures, and secondarily elevated parathyroid
hormone.
Table 1: Recommended daily calcium and vitamin D
∗
3 intake.
Adult women and
men
Calcium Vitamin D3
During periods of
rapid weight loss
1,500–2000mg 1,000IU
Morbidly obese
patients
1,500mg 2,000IU
Post-Bariatric
surgery patients
1,500–2000mg 2,000IU–100,000+ IU
∗Doses listed are for maintenance of normal levels. Repletion of vitamin D
often requires signiﬁcantly higher doses.
Correction of vitamin D deﬁciency in bariatric surgery
patientsrequiresmorethanjustanover-the-countermultivi-
tamin.Repletionhasbeensafelyachievedbygiving50,000IU
to 100,000IU cholecalciferol daily for one to two weeks
followed by a maintenance dose of 50,000 one to three
times weekly. Ergocalciferol as well as the various vitamin
D analogs have not demonstrated the eﬃcacy achieved with
cholecalciferol in normalizing blood values or addressing
symptoms [42, 43].
The absorption of vitamin D is dependant upon the
presence of bile acids. Predictably, it has been demonstrated
that taking cholecalciferol with the largest meal of the day
promotes improved uptake [44]. And for patients who are
unable to achieve normal serum levels with oral supplemen-
tation, UV-B phototherapy is an eﬀective alternative [3, 4,
45, 46]. Having said that, the use of tanning beds, although
advocated by few, is not recommended due to the fact that
the average tanning bulb emits 95% UVA and 5% UVB
radiation,impartsa4-foldto15-foldhigherdoseofUVAand
2-fold higher dose of UVB than summer, noontime casual
sun exposure, and have been implicated in the development
of skin cancers [47, 48].
11.2. Cholestyramine. Originally marketed as an eﬀective
drug for the reduction of plasma cholesterol because of its
ability to sequester intestinal bile acids, cholestyramine is
now commonly prescribed for the symptomatic relief of
diarrhea. When the drug is used on a short-term basis,
there does not seem to be cause for concern however, when
prescribed long term as is often the case in bariatric surgery
patients, there is an increased risk for alterations in vitamin
and mineral metabolism due to the resin’s bile acid-binding
characteristics [49] ,a n dr i s ko fb o w e lo b s t r u c t i o n[ 50, 51].
Studies conducted in rodents that date back to the
1970s demonstrated a net negative balance for calcium,
inadequate vitamin D absorption, and a subsequent increase
in parathyroid hormone secretion due to cholestyramine.
Frank osteomalacia was also noted but was found to be
reversible with vitamin D supplementation [49]. Subsequent
human studies conﬁrmed the relationship between chronic
use of bile acid resins, impaired vitamin D absorption,
and osteomalacia [52] while at least one longitudinal study
refutes the eﬀect on the availability of vitamin D and the
development of secondary hyperparathyroidism [53].6 Journal of Obesity
The evidence regarding the risk of bowel obstruction
due to cholestyramine is more scanty, almost exclusively in
the pediatric population, and predominantly in the form of
case reports dating back to the late 1960s [54, 55]. The lone
exception is a review published in 2007 that while exam-
ining safety considerations noted that moderate-to-severe
constipation was common, and subsequently compelled the
authors to recommend that cholestyramine and other bile
acid sequestrants are to “be avoided in patients with recent
abdominal surgery and in patients with recent or repeated
episodes of intestinal obstruction” [56].
12. Bisphosphonate Use in
BariatricSurgeryPatients
When a bone loss disease occurs in a bariatric surgery
patient, secondary disease should be suspected ﬁrst, and it
is the secondary disease that deserves the primary focus of
treatment interventions. The etiology of conﬁrmed vitamin
D deﬁciency, hypocalcemia, elevated alkaline phosphatase,
secondary hyperparathyroidism, and accompanying signs
and symptoms should be clearly delineated to the degree
possible, and appropriate treatment interventions initiated.
Abnormal DXA may be indicative of both primary and
secondary disease however aggressive treatment of the
underlying cause of the secondary disease can result in
signiﬁcant improvements in BMD [41].
Clinical and biochemical resolution of secondary bone
disease in the presence of persistently abnormal DXA should
prompt treatment considerations for primary bone disease,
however concern remains when considering the use of
oral bisphosphonates in bariatric surgery patients due to
the lack of safely and eﬃcacy data. Speciﬁcally, tolerance
has not been established in the surgical gut, and risk of
ulceration at surgical anastamosis has not been deﬁned.
Eﬃcacy of oral bisphosphonates has also come into question
following intestinal procedures after which the drug may be
malabsorbed. It is for these reasons that if a bisphosphonate
is indicated, unless there is evidence to the contrary,
intravenous administration is recommended.
13. ProteinandBone Health
A systematic review of protein and bone health concluded
that diets containing 1.0–1.5g/kg protein are typically opti-
mal for bone health [57]. This is particularly worrisome,
in that this suggests the current RDA of 0.8gprotein/kg
is insuﬃcient to promote calcium homeostasis. Similarly,
the common practice of prescribing 60 to 80 grams of
protein after bariatric surgery is often wholly inadequate. It
is essential to use an adjusted body weight that approximates
metabolically active tissue when calculating protein needs as
there is also a link between excessive protein intake, calciuria,
and increased fracture risk [58, 59].
14.BariatricOsteomalacia:
AnEvolvingConcept
Prior to recent investigations in metabolic bone disease and
bariatric surgery, improvement in bone density as a result
of vitamin D supplementation had been demonstrated
however, the changes were small, of questionable clinical
signiﬁcance, and occurred exclusively in trabecular bone
[60].
Bariatric osteomalacia appears to be a unique disorder in
that profound improvement in symptoms and bone mineral
density measurements have been observed in response
to aggressive oral repletion with pharmacologic doses of
cholecalciferol and calcium citrate (Figure 3). It has been
proposed that these observed responses may be unique
to bariatric surgery patients, is a synergistic and graded
response of D3 and calcium citrate based on the magnitude
of the deﬁciencies, and that D3 likely has a hormonal eﬀect
on cortical bone that is more pronounced in this patient
population [41, 61]. Studies are currently underway in an
eﬀort to conﬁrm the observations, characterize the patho-
physiology,anddeﬁnediagnosis,treatment,andpreventative
guidelines for this increasingly common disorder.
15. Summary
Bariatric surgery has proven to be an eﬀective and life-saving
measure that provides sustainable weight loss but it is not
without risk of complications, to include metabolic bone
disease.
T h e r ei sac a u s a l ,m u l t i f a c t o r i a lr e l a t i o n s h i pb e t w e e n
bariatricsurgeryandMBDandforthatreasonMBDremains
an ever-present risk in bariatric surgery patients. Patients
presentingforbariatricsurgeryshouldbeevaluatedforMBD
and receive appropriate presurgical interventions. Postsur-
gically, the importance of consuming adequate protein and
the correct combination of vitamins and minerals cannot be
overstated,rememberingthatnobariatricsurgicalprocedure
is risk-free when it comes to the development of metabolic
bone disease.
As clinicians, we cannot assume that our morbidly obese
patients are well nourished or that they have normal bone
quality. Dual-energy X-ray absorptiometry can be used to
help assess bone status in the morbidly obese, however if
the DXA table limitations prevent imaging the hips and
spine, the nondominant forearm is a validated option for
quantifying bone mineral density.
Not all abnormal DXA results represent primary osteo-
porosis and in fact, in the bariatric population, secondary
bone disease is the norm and when the diagnosis has been
conﬁrmed, treating the underlying cause of the secondary
disease must take precedent. DXA Z-scores, if abnormally
low, suggest the presence of secondary MBD, however it
is important to remember that secondary disease can be
present even in the presence of normal scores. Clues such as
proximal weakness, a history of renal oxalate stones, chronic
steatorrhea, and undersupplementation should serve to alert
the clinician to the possible presence of metabolic bone
disease.
In addition to the AACE/TOS/ASMBS guidelines, a
baselineandoneyearpostoperativeDXAsarerecommended.
The use of calcium citrate and cholecalciferol (vitamin D3)
are the recommended forms of these supplements, and in
order to achieve and maintain normal serum levels, veryJournal of Obesity 7
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Figure 3: Bone remineralization following aggressive oral repletion with cholecalciferol and calcium citrate.
high doses are often required in the bariatric postoperative
patient.
Caution is advised when considering the use of certain
medications to treat common problems in this patient popu-
lation.Cholestyramineorotherbileacidsequestrantsusedto
control diarrhea in this patient population increase the risk
of exacerbating vitamin D malabsorption and osteomalacia,
and may increase the risk of bowel obstruction. The use of
bisphosphonates for presumed osteoporosis carries the risk
of life-threatening hypocalcemia; eﬃcacy has not been well
established in this population, and the risk for ulceration
from oral preparations at the surgical anastamosis has yet to
be delineated.
Finally, there is emerging evidence that bariatric osteo-
malacia is a unique and increasingly common phenomenon
in bariatric surgery patients that can have a subtle clinical
presentation but potentially devastating consequences if left
unrecognized. Investigations into the underlying mechanism
of the disease, the response to aggressive repletion, and
eﬀective preventive strategies are ongoing. The treatment
regimen at this point in time includes the use of chole-
calciferol and calcium citrate with frequent monitoring
and dose adjustments to attain and maintain normal lab
parameters.
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